Clinical Trial

Multiple Ascending Dose Phase 1 Study of ALA-3000

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-02; most recent amendment 2025-12-30.
Status change: Active, Not Recruiting → Completed 2025-12-30
Status change: Recruiting → Active, Not Recruiting 2025-10-27
Trial Details
NCT Number NCT06965569
Lead Sponsor Alar Pharmaceuticals Inc.
Conditions Treatment Resistant Depression
Enrollment 37 participants
Start Date 2025-04-21
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-31